Funding for this research was provided by:
Gebro Pharma
Article History
Received: 14 March 2018
Revised: 24 August 2018
Accepted: 24 August 2018
First Online: 28 September 2018
Competing interests
: M.B. has received speaker fees from Grifols, Menarini, GSK and consulting fees from Novartis and Gebro Pharma. M.M. has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Grifols and Novartis, and consulting fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Gebro Pharma, CSL Behring, Novartis and Grifols. The other author declares no competing interests.